Beta-blockers — principally propranolol — occupy a definite pharmacological specialized niche in SAD administration. They do not modify central risk circuitry or generate inhibitory Studying.Phenibut: Not FDA-permitted, not issue to pharmaceutical top quality control, carries sizeable dependence chance, and has no managed trial proof foundation